Yttrium Y-90
- Generic Name
- Yttrium Y-90
- Brand Names
- Yttriga
- Drug Type
- Small Molecule
- Chemical Formula
- Y
- CAS Number
- 10098-91-6
- Unique Ingredient Identifier
- 1K8M7UR6O1
- Background
Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.
- Associated Conditions
- Radiollabeling
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
- Conditions
- Hepatocellular Carcinoma (HCC)Macrovascular InvasionLiver Transplant SurgeryDownstaging
- Interventions
- Radiation: Stereotactic body radiotherapy (SBRT)
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 48
- Registration Number
- NCT06725121
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06447727
- Locations
- 🇨🇳
Zhongda Hospital，Southeast University, Nanjing, Jiangsu, China
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05195710
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
- Conditions
- Liver Malignancy
- Interventions
- Device: Selective Internal Radiation TherapyRadiation: Stereotactic Body Radiation TherapyDiagnostic Test: PET/CTDevice: Therasphere
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT04518748
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Treatment for Bile Duct Cancer in the Liver
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 24
- Registration Number
- NCT02167711
- Locations
- 🇭🇰
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 24
- Registration Number
- NCT00846131
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
- Conditions
- Kidney NeoplasmRenal CancerRenal Cell CarcinomaKidney Cancer
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 18
- Registration Number
- NCT00199875
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
- Conditions
- Leukemia, T-CellLymphoma, T-Cell, Cutaneous
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001249
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.